Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Part of paid clinical trials in San Antonio, Texas.
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Study ID
- NCT03160274
- Status
- Recruiting
Conditions
- Associated Conditions
- Bone Cancer
- Inherited Cancer Syndrome
- Kidney Neoplasms
- Other Cancer
- Paraganglioma
- Pheochromocytoma
- Thyroid Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Interventions
- Genetic screening — GENETICGermline and/or tumor samples will be screened for mutations
Study Details
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.
Key Dates
- Start date
- Oct 19, 2005
- Status verified
- Oct 2025
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 2,000 participants (estimated)
Primary Outcome Measure
Identification of germline driver mutation [ Time Frame: through study completion- average time approximately 6 months ]
Central Contacts
- Patricia L Dahia, MD,PhD2105674866
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Health Science Center | San Antonio | Texas | 78229 |
Find similar trials in San Antonio, TX
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Diagnosis of PheochromocytomaPHASE1 · Recruiting · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Bethesda, Maryland
- Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York